Pfizer today said it won't apply for an emergency use authorization for its COVID-19 vaccine until late November, all but guaranteeing that the FDA won't be asked to consider approval until after the election.
Axios Re:Capgoes deeper with Moncef Slaoui, the White House's top scientific advisor to Operation Warp Speed, the public-private partnership created to get a coronavirus vaccine deployed and developed.
